Publications

Publications

Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery.

By:
Contributors: Andries Zijlstra Research Group, John D. Lewis Research Group, Desmond Pink, PhD
PLoS One. 2012;7(3):e33760. doi: 10.1371/journal.pone.0033760. Epub 2012 Mar 29.

Abstract

The leaky, heterogeneous vasculature of human tumors prevents the even distribution of systemic drugs within cancer tissues. However, techniques for studying vascular delivery systems in vivo often require complex mammalian models and time-consuming, surgical protocols. The developing chicken embryo is a well-established model for human cancer that is easily accessible for tumor imaging. To assess this model for the in vivo analysis of tumor permeability, human tumors were grown on the chorioallantoic membrane (CAM), a thin vascular membrane which overlays the growing chick embryo. The real-time movement of small fluorescent dextrans through the tumor vasculature and surrounding tissues were used to measure vascular leak within tumor xenografts. Dextran extravasation within tumor sites was selectively enhanced an interleukin-2 (IL-2) peptide fragment or vascular endothelial growth factor (VEGF). VEGF treatment increased vascular leak in the tumor core relative to surrounding normal tissue and increased doxorubicin uptake in human tumor xenografts. This new system easily visualizes vascular permeability changes in vivo and suggests that vascular permeability may be manipulated to improve chemotherapeutic targeting to tumors.

PubMed

Download PDF

APCaRI members participate in the 2016 CCI Golf Classic

Members of the APCaRI team felt very fortunate yesterday to participate in the Alberta Cancer Foundation’s 28th Annual Cross Cancer Institute Golf Classic – a wonderful event that has raised more than $12 million to pioneer revolutionary projects in support of patients at Alberta’s own Cross Cancer Institute and beyond.

Over the past 27 years, the Cross Cancer Institute Golf Classic has funded leading edge research, treatment and patient care programs at the Cross Cancer Institute. In 2016, the Alberta Cancer Foundation embarked on a new investment that will bring together the brightest minds in colorectal cancer research to increase survival rates and improve quality of life for colorectal patients across the province.

Heartfelt thanks to the amazing volunteers, the organizing committee, the Alberta Cancer Foundation, and all of the participants!

 

 

 

- Catalina Vasquez